Core Viewpoint - The company has received approval for the production and sale of Moxifloxacin Hydrochloride Tablets, enhancing its product portfolio in the anti-infection sector [1][2]. Group 1: Product Approval - The company's wholly-owned subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Moxifloxacin Hydrochloride Tablets from the National Medical Products Administration [1]. - Moxifloxacin is a broad-spectrum antibacterial agent effective against various bacteria, including Gram-positive, Gram-negative, anaerobic, and atypical microorganisms [1]. Group 2: Market Impact - The approval allows the company to expand its core product offerings in the anti-infection field, thereby increasing its competitiveness in the systemic anti-infection market [2]. - The introduction of Moxifloxacin Hydrochloride Tablets will not have a significant impact on the company's current operating performance [2].

Core Viewpoint - The announcement by Zhenbao Island (603567) regarding the approval of moxifloxacin hydrochloride tablets by the National Medical Products Administration indicates a significant development in the company's pharmaceutical portfolio, potentially enhancing its market position in the antibacterial drug segment [1] Group 1: Company Developments - Zhenbao Island's wholly-owned subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., has received the drug registration certificate for moxifloxacin hydrochloride tablets [1] - The company has invested approximately 13.64 million RMB in the research and development of this drug [1] Group 2: Market Context - Moxifloxacin hydrochloride is a broad-spectrum antibacterial agent used for treating various bacterial infections [1] - There are currently 24 approved manufacturers of moxifloxacin hydrochloride tablets in China, with a market size reaching 530 million RMB [1] - The production and sales of this drug are subject to significant uncertainties due to national policies and market environment changes [1]

Core Viewpoint - The announcement from the Heilongjiang Provincial Drug Administration confirms that the inspections conducted on Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. and Harbin Fangsheng Pharmaceutical Technology Co., Ltd. have met the GAP (Good Agricultural Practices) requirements for traditional Chinese medicine materials [3]. Group 1: Inspection Results - The inspections were carried out from November 7 to November 9, 2025, and the results indicated compliance with GAP standards [3]. - Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. has a cultivation area of 2,920 acres, with an expected yield of 150,020 kg for its Astragalus injection products [3]. - Harbin Fangsheng Pharmaceutical Technology Co., Ltd. has a cultivation area of 3,120 acres, with an expected yield of 159,380 kg for its Astragalus injection products [3]. Group 2: Product Specifications - Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. produces Astragalus injections in two specifications: 10ml (National Drug Approval Number Z23020782) and 20ml (National Drug Approval Number Z23020862) [3]. - Harbin Fangsheng Pharmaceutical Technology Co., Ltd. produces Astragalus injections in a 2ml specification (National Drug Approval Number Z23020781) [3]. Group 3: Geographic Information - The geographic coordinates for Heilongjiang Zhenbaodao's cultivation base include multiple points: - Point 1: East Longitude 104°31′457″, North Latitude 34°40′529″ - Point 2: East Longitude 104°32′719″, North Latitude 34°41′333″ - Point 3: East Longitude 104°32′839″, North Latitude 34°39′273″ - Point 4: East Longitude 104°31′784″, North Latitude 34°38′567″ [3]. - The geographic coordinates for Harbin Fangsheng's cultivation base also include multiple points: - Point 1: East Longitude 104°34′194″, North Latitude 34°41′713″ - Point 2: East Longitude 104°32′735″, North Latitude 34°41′218″ - Point 3: East Longitude 104°35′038″, North Latitude 34°41′439″ - Point 4: East Longitude 104°33′261″, North Latitude 34°39′796″ [4].

证券日报网讯12月1日，珍宝岛（603567）在互动平台回答投资者提问时表示，公司高度重视和关注公 司价值及股东利益，将持续聚焦主业，优化经营管理，积极探索更多的发展机会，同时通过增强信息披 露透明度、持续加强与各市场主体的沟通交流等方式积极开展市值管理工作，传递经营理念和投资价 值，更好地实现公司的长远发展和股东回报。关于股份回购或增持计划，公司将结合市场环境、资金状 况及监管要求统筹考量，如有具体计划将按规定及时披露。 ...

近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"） 收到控股股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达 集团 2023 年面向专业投资者非公开发行可交换公司债券（第一期）（以下简称"第 一期可交债"）换股价格将进行调整，现将有关事项公告如下： 一、控股股东可交换公司债券的基本情况 公司控股股东创达集团已于 2023 年 4 月 11 日完成第一期可交债的发行。本 期可交债简称"23 创 01EB"，债券代码"137171"，发行规模 9.1 亿元，债券期 限 3 年。具体内容详见公司于 2023 年 4 月 12 日在上海证券交易所网站披露的临 2023-019 号公告。 二、控股股东可交换公司债券本次换股价格调整情况 证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-080 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 换股价格调整的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 黑龙江珍宝岛药业股份有限公司董事会 2025 年 11 月 ...

Group 1 - The Chinese medicine sector experienced a decline of 0.83% on November 28, with Yue Wannianqing leading the drop [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Key stocks in the Chinese medicine sector showed mixed performance, with Tai Long Pharmaceutical rising by 5.37% to a closing price of 8.04 [1] Group 2 - Yue Wannianqing saw a significant drop of 13.71%, closing at 22.84, with a trading volume of 296,100 shares [2] - Other notable declines included Zhongsheng Pharmaceutical, which fell by 10.00% to 23.95, and Te Yi Pharmaceutical, which decreased by 6.41% to 14.01 [2] - The overall net capital flow in the Chinese medicine sector indicated a net outflow of 981 million yuan from main funds, while retail investors contributed a net inflow of 766 million yuan [2]

Group 1 - The company will hold its third extraordinary general meeting of shareholders on December 11, 2025, at 14:00 in Harbin [2][5][11] - The voting method for the meeting will combine on-site voting and online voting through the Shanghai Stock Exchange's network voting system [3][5] - The online voting will be available on the same day from 9:15 to 15:00, with specific time slots for trading system voting [3][7] Group 2 - The board of directors has approved the proposal to renew the appointment of the auditing firm Zhongshui Yatai for the 2025 fiscal year, with a fee of RMB 1.5 million [21][25] - The auditing firm has a history of providing services since its establishment in 1993 and has a significant number of registered accountants [26][27] - The proposal for the renewal of the auditing firm will also be submitted for approval at the upcoming extraordinary general meeting [34][35]

Core Viewpoint - The company, Zhenbaodao, announced its board meeting to discuss the reappointment of the auditing firm for the fiscal year 2025, indicating ongoing governance and compliance efforts [1] Financial Performance - For the fiscal year 2024, Zhenbaodao's revenue composition is as follows: pharmaceutical manufacturing accounts for 87.78%, pharmaceutical distribution for 11.13%, and other businesses for 1.09% [1] - The current market capitalization of Zhenbaodao is 9.7 billion yuan [1] Regulatory Issues - Another company, identified as 688496, is under investigation by the China Securities Regulatory Commission (CSRC) due to a significant loss exceeding 100 million yuan shortly after its IPO, with its main customer reducing purchases [1]

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-078 黑龙江珍宝岛药业股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （6）人员信息： ●拟续聘的会计师事务所名称：中审亚太会计师事务所（特殊普通合伙）（以 下简称"中审亚太"） 公司于 2025 年 11 月 24 日召开的第五届董事会第二十八次会议审议并通过 了《关于续聘公司 2025 年度审计机构的议案》，拟续聘中审亚太为公司 2025 年度财务报告及内部控制审计机构，本事项尚需提交公司 2025 年第三次临时股 东会审议。现将相关事项公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 （1）机构名称：中审亚太会计师事务所（特殊普通合伙） （2）成立日期：1993 年 3 月 2 日（中审亚太会计师事务所（特殊普通合伙） 前身为中国审计事务所，后经合并改制于 2013 年 1 月 18 日变更为中审亚太会计 师事务所（特殊普通合伙））。 （3）组织形式：特殊普通合伙 （4） ...

(一) 股东会类型和届次 2025年第三次临时股东会 证券代码：603567 证券简称：珍宝岛 公告编号：临2025-079 黑龙江珍宝岛药业股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 11 日 至2025 年 12 月 11 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市 ...